Molecular markers (PECAM-1, ICAM-3, HLA-DR) determine prognosis in primary non-Hodgkin&rsquo;s gastric lymphoma patients

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 12

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

287

HTML

2062

Figures (1-5)

144

Tables (1-7)

130

Sum=2623

Mar 28, 2006 (publication date) through Apr 30, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Research

World J Gastroenterol. Mar 28, 2006; 12(12): 1924-1932
Published online Mar 28, 2006. doi: 10.3748/wjg.v12.i12.1924

Full Size Figure Download Figure

Figure 5 One hundred percent 5-year survival rate in HLA-DR(+)/ICAM-3(+)/PECAM-1(-) gastric lymphoma patients.

Citation: Darom A, Gomatos IP, Leandros E, Chatzigianni E, Panousopoulos D, Konstadoulakis MM, Androulakis G. Molecular markers (PECAM-1, ICAM-3, HLA-DR) determine prognosis in primary non-Hodgkin’s gastric lymphoma patients. World J Gastroenterol 2006; 12(12): 1924-1932
URL: https://www.wjgnet.com/1007-9327/full/v12/i12/1924.htm
DOI: https://dx.doi.org/10.3748/wjg.v12.i12.1924